DEPO Depomed, Inc.

11.68
+0  (1%)
Previous Close 11.57
Open 11.62
Price To book 2.86
Market Cap 725.32M
Shares 62,099,000
Volume 1,063,546
Short Ratio 8.14
Av. Daily Volume 1,583,380

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved January 28, 2011.
GRALISE
Postherpetic neuralgia - shingles
CRL issued May 31, 2013.
SEFELSA
Hot flashes

Latest News

  1. Depomed Announces Appointment of Sharon D. Larkin as Senior Vice President, Human Resources and Administration
  2. Which Drugmakers Will Rock The Sector In Q1?
  3. STRATA Skin Sciences and Depomed Recover from Wednesday's FDA Opioid Shockwave
  4. DepoMed, Opioid Makers Fall After Trump's FDA Pick Says America's Drug Addiction Is Out of Control
  5. Depomed Announces Prepayment of $100 Million of Secured Debt Facility
  6. Biotech Premarket Movers: Sage Therapeutics, Depomed, NantKwest
  7. How Much Pain Will Congress Inflict on These Opioid Drugmakers' Stocks?
  8. Will This Biotech Survive Activist Investor — Or Get Taken Over?
  9. Checkmate: Starboard Boots Depomed CEO, Two Board Members
  10. ($$) Starboard Wins More Board Seats, Replaces CEO at Depomed
  11. Biotech Premarket Movers: Vertex, Sangamo, Depomed
  12. Depomed Board of Directors Shaken Up While Insys Therapeutics Appoints a New CEO
  13. Depomed Switches Out CEO and Board in Making Peace With Activist Starboard
  14. Depomed names new CEO, directors in deal with activist Starboard
  15. ($$) Senator McCaskill Begins Probe of Prescription Opioid Marketing
  16. Depomed names new CEO
  17. Depomed dives as activist investor fight leads to new CEO, board members
  18. Depomed Announces Cooperation Agreement with Starboard Value LP Including CEO and Board Changes
  19. Senator McCaskill Launching Investigation Into Opioid Drugmakers
  20. CFO Says Depomed to Buy or Be Sold